Business Context and Reporting Period
Company: Humana Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Humana operates two primary segments: Insurance (Medicare Advantage, Medicaid, Commercial, and Military services) and CenterWell (Pharmacy, Primary Care, and Home Solutions). As of December 31, 2024, the Company served approximately 16 million medical members and 5 million specialty members. Approximately 85% of total premiums and services revenue is derived from federal government contracts, with significant concentration in Medicare Advantage plans.
Key Financial Metrics
| Metric (in millions, except per share) | 2024 | 2023 |
|---|---|---|
| Total Revenues | $117,761 | $106,374 |
| Net Income Attributable to Humana | $1,207 | $2,489 |
| Diluted Earnings Per Share | $9.98 | $20.00 |
| Operating Cash Flow | $2,966 | $3,981 |
| Benefit Ratio | 89.8% | 87.3% |
| Operating Cost Ratio | 11.8% | 12.5% |
| Total Debt (Short-term + Long-term) | $11,721 | $11,656 |
| Cash and Cash Equivalents | $2,221 | $4,694 |
Material Changes vs. Prior Period
- Profitability Decline: Net income decreased 51.1% to $1.2 billion, and diluted EPS fell 50.1% to $9.98. This decline was driven by higher medical cost trends, lower favorable prior-period reserve development, and specific charges including $281 million in value creation initiatives and $200 million in impairment charges.
- Revenue Growth: Total revenues increased 10.7% to $117.8 billion, primarily due to higher per-member Medicare premiums and membership growth in Medicare Advantage and state-based contracts. This was partially offset by a decline in stand-alone PDP membership and the exit from the Employer Group Commercial Medical Products business.
- Benefit Ratio Deterioration: The consolidated benefit ratio increased 250 basis points to 89.8%, reflecting elevated medical cost trends and reduced favorable reserve development ($701 million in 2024 vs. $872 million in 2023).
- Operating Efficiency: The operating cost ratio improved 70 basis points to 11.8%, aided by scale efficiencies and administrative cost savings from value creation initiatives.
- Membership Shifts: Individual Medicare Advantage membership grew 4.7% to 5.66 million. Conversely, Medicare stand-alone PDP membership declined 19.7% due to competition, and Commercial fully-insured membership dropped 99.9% as the Company executes its exit strategy.
Guidance, Outlook, and Risks
- 2025 Membership Outlook: Management anticipates a net decline of approximately 550,000 members in Individual Medicare Advantage offerings for 2025. Group Medicare Advantage is expected to be relatively flat, while State-based contracts are projected to grow by 175,000 to 250,000 members.
- Star Ratings Litigation: Approximately 25% of Medicare Advantage members are enrolled in plans rated 4-star or higher for 2025, a significant drop from 94% in 2024. Humana has filed a lawsuit to vacate the 2025 Star Ratings, arguing the methodology violates the Administrative Procedure Act. A loss could negatively impact 2026 quality bonus payments and future revenues.
- Regulatory Risks: The Company faces ongoing risks related to the CMS Risk-Adjustment Data Validation (RADV) audit methodology, specifically the elimination of the "Fee-for-Service Adjuster." Humana is litigating this rule change, which could materially affect cash flows if extrapolated recoveries are applied without the adjuster.
- Commercial Exit: The Company plans to finalize its exit from the Employer Group Commercial Medical Products business in the first half of 2025.
- Legal Proceedings: Humana settled a qui tam suit regarding Medicare Part C risk adjustment practices in August 2024 for $90 million. The Company is also defending against securities class action litigation regarding financial performance and Star Ratings disclosures.
Investor Verification Checklist
- Star Rating Impact: Verify the outcome of the lawsuit challenging the 2025 Star Ratings and the potential financial impact on 2026 quality bonuses.
- Medical Cost Trends: Monitor the trajectory of the benefit ratio in 2025 to determine if elevated medical cost trends persist or if pricing adjustments are effective.
- RADV Litigation: Track the status of the lawsuit regarding the CMS RADV Final Rule and the potential for retroactive recoveries without the FFS Adjuster.
- Commercial Exit Execution: Confirm the timeline and financial impact of the final exit from the Employer Group Commercial Medical Products business in H1 2025.
- Liquidity Position: Review the reduction in cash and cash equivalents (from $4.7B to $2.2B) and the Company's ability to fund operations and debt obligations given the lower operating cash flow.